Cervical Cancer Vaccination: What You Need to Know

Vaccination against cervical cancer is actually vaccination against the human papillomavirus. Almost all cases of cervical cancer are associated with oncogenic types of this virus. The World Health Organization notes that almost all sexually active people become infected with the human papillomavirus at some point in their lives, most often asymptomatically, and the danger arises when the infection persists for years. [1]

It's important to understand that the human papillomavirus itself is linked to more than just cervical cancer. The US National Cancer Institute notes that persistent infection with high-oncogenic types can lead to six types of cancer: cervical, anal, oropharyngeal, penile, vaginal, and vulvar. Therefore, this isn't a "female vaccine for a single disease," but rather a broad-based prevention strategy for tumors associated with the human papillomavirus. [2]

The biological logic here is very simple. Most infections resolve spontaneously, but if a highly oncogenic virus persists, precancerous changes gradually accumulate in the cells of the cervix and other tissues. The World Health Organization notes that the path from persistent infection to cancer typically takes 15-20 years, but in people with severe immunodeficiency, it can proceed more quickly, sometimes within 5-10 years. This is what makes vaccination particularly valuable: it intervenes in the process long before the disease appears. [3]

Another important principle is that this vaccine is preventative, not curative. The US Centers for Disease Control and Prevention clearly emphasize that the vaccine prevents new infections, but does not treat an existing infection or established disease. This is why the maximum effect is achieved before the onset of sexual activity and before first exposure to the virus. [4]

From a public health perspective, this vaccination is one of the three pillars of the cervical cancer elimination strategy. The World Health Organization has set a 90, 70, 90 target by 2030: 90% of girls should be fully vaccinated by age 15, 70% of women should receive high-quality screening by age 35 and 45, and 90% of women with precancer and cancer should receive treatment. This underscores the key message: vaccination is crucial, but it works best when combined with screening and timely treatment. [5]

What exactly is associated with the human papillomavirus?	What does vaccination provide?
Cervical cancer	Reduces the risk of new infection with highly oncogenic types
Anal cancer	Reduces the risk of some virus-associated tumors
Oropharyngeal cancer	Reduces the likelihood of infection by the types associated with these tumors
Penile cancer	Provides protection to men too
Vaginal and vulvar cancer	Reduces the risk of some precancerous and tumorous conditions
Genital warts	The nonavalent and quadrivalent vaccines also protect against types 6 and 11.

Sources for table: US National Cancer Institute and US Centers for Disease Control and Prevention. [6]

Who especially needs vaccination and at what age is it most beneficial?

The vaccine is most effective when administered before potential exposure to the virus. Therefore, the World Health Organization considers girls aged 9-14 years to be the primary target group, while the US Centers for Disease Control and Prevention recommends routine vaccination at 11-12 years of age, with the possibility of starting as early as 9 years of age. These approaches are not contradictory: both systems believe the optimal window is late childhood and early adolescence. [7]

A gender-neutral approach is increasingly being used in modern prevention. The World Health Organization emphasizes that girls remain the top priority for the global elimination of cervical cancer, but vaccination of boys and older age groups is recommended where possible and accessible. This approach makes clinical sense because the virus also causes cancer in men, and reducing viral circulation in the population also protects those who are unvaccinated. [8]

If a vaccination was not administered on time, this does not mean it is no longer useful. The US National Cancer Institute and the US Centers for Disease Control and Prevention recommend catch-up vaccination before age 26 for those who were not previously vaccinated or did not complete the course. The benefit in such cases is usually lower than with vaccination at ages 9-14, but it can still be significant because a person is rarely infected with all the types of viruses that the vaccine protects against. [9]

There is no universal recommendation for adults aged 27-45. The US Centers for Disease Control and Prevention (CDC) states that vaccination is not routine for everyone at this age and is more often discussed on an individual basis, based on the likelihood of new infections and previous vaccination status. The reason is simple: by this age, many have already encountered the virus, so the expected additional benefit is, on average, lower. [10]

A separate group consists of people with immunodeficiency, including those living with the human immunodeficiency virus. For them, protection is especially important because persistent infection and the transition to precancerous changes can occur more quickly. Therefore, both the World Health Organization and the US Centers for Disease Control and Prevention emphasize that these patients often require more comprehensive vaccination schedules rather than simplified versions. [11]

Group	What is known from current recommendations?
Girls 9-14 years old	The main target group for maximum preventive effect
Boys 9-14 years old	Many programs also vaccinate for personal and community protection.
Teenagers and young adults up to 26 years of age	Catch-up vaccination is usually recommended if the course is not completed.
Adults 27-45 years old	The decision is often made individually
People with immunodeficiency	Usually a more complete diagram is needed
Pregnant women	The start of the course is usually postponed until the end of pregnancy.

Sources for the table: World Health Organization, US Centers for Disease Control and Prevention, US National Cancer Institute. [12]

How many doses are needed and why different regimens are seen in different countries

It's the section on doses that's currently causing the most confusion. Historically, most programs were structured according to age-specific logic: if the course began before age 15, two doses were sufficient, and if at age 15 or older, three doses were used. The US Centers for Disease Control and Prevention still formulates recommendations this way: two doses for most people who started vaccination before age 15, and three doses for those who started between ages 15 and 26, as well as for those with immunodeficiencies. [13]

With a two-dose regimen, the interval is important. The US Centers for Disease Control and Prevention recommends giving the second dose 6-12 months after the first, and if the two doses are given too close together, less than 5 months apart, a third may be needed. This is a technical but important detail, because failure to adhere to the minimum intervals often creates the impression that the course is "done," even though, according to the rules, it is not yet complete. [14]

The World Health Organization has approved a more flexible approach since 2022. It currently allows for one or two doses for girls aged 9-14 and for young women aged 15-20, two doses for women over 21, and at least two, and possibly three, doses for immunocompromised patients. This means that in practice today, two models coexist: the traditional age-based model and the expanding single-dose model. [15]

New data continues to strengthen the case for the single-dose regimen. In January 2026, the US National Institutes of Health reported the results of a study in which one dose demonstrated protection comparable to two doses, with efficacy in preventing persistent infection with types 16 and 18 at least 97%. However, even such strong data does not mean that every country is obligated to immediately change its schedule: national programs are modified gradually, after assessing regulatory, logistical, and economic factors. [16]

The practical conclusion for patients is very simple. Don't rely on random advice from the internet or on the schedule of friends from another country. The schedule should be checked against the current calendar of the specific country and healthcare system where vaccinations are administered, and in cases of immunodeficiency or pregnancy, individual medical circumstances must be taken into account. [17]

Situation	The most typical modern approach
Initiation of vaccination in early adolescence	Often 1 or 2 doses according to the national calendar
Onset after 15 years	Many programs store 3 doses
Immunodeficiency	Usually at least 2 doses, often 3
Pregnancy during the course	The following doses are usually delayed
Too early interval between first doses	An additional dose may be required.
Interrupted course	Usually they don't start over, but continue according to the current rules

Sources for table: World Health Organization, US Centers for Disease Control and Prevention, US National Cancer Institute. [18]

What have real-life effectiveness studies shown?

For a long time, efficacy was assessed based on the reduction in infection and precancerous changes, as the time from infection to invasive cancer can take years. Now, more stringent endpoints are being considered. The US National Cancer Institute emphasizes that clinical trials and real-world population data have shown a significant reduction in the risk of precancer and cancer of the cervix, vagina, and vulva in vaccinated women, especially if vaccination was administered before initial exposure to the virus. [19]

One of the most well-known pieces of evidence was a Swedish study. The US National Cancer Institute reported that in a study of nearly 1.7 million women, vaccination was associated with a sharp reduction in the incidence of invasive cervical cancer, and among those vaccinated before age 17, the reduction in incidence was nearly 90% compared to those not vaccinated. This is no longer an intermediate marker, but a true reduction in cancer itself. [20]

Data on precancer is also very important, as it allows us to see the program's impact earlier. A 2025 report from the US Centers for Disease Control and Prevention showed that among women aged 20-24 examined, the incidence of precancerous cervical lesions of grade 2 and higher decreased by 79% between 2008 and 2022, and the most severe precancers of grade 3 and higher decreased by 80%. A reduction in severe precancers was also shown for those aged 25-29. [21]

A separate important conclusion concerns the age of vaccination. Both Swedish data and American observations show the same pattern: the earlier the vaccine is administered, the stronger the population effect. This does not mean that catch-up vaccination is useless, but it confirms that a preventive strategy is most effective before infection, not after. [22]

There is also data on the duration of protection. The US Centers for Disease Control and Prevention reports that vaccinated individuals have been monitored for over 12 years, and no signs of significant weakening of protection have been detected during this time. The US National Cancer Institute similarly points to long-term durability of protection for various vaccines, although research into long-term immunity is ongoing. [23]

Research or data type	The main conclusion
Clinical trials before registration	Very high protection against target virus types and associated precancers
Swedish population study	Nearly 90% reduction in risk of invasive cervical cancer with vaccination before age 17
The Centers for Disease Control and Prevention's Precancer Surveillance	Marked reduction in severe precancers in young women who were vaccinated as adolescents
2025 study on single-dose regimen	A single-dose regimen showed comparable protection against persistent infection with types 16 and 18
Long-term observation	The protection lasts for many years without obvious signs of rapid decline.

Sources for the table: US National Cancer Institute, US Centers for Disease Control and Prevention, US National Institutes of Health. [24]

Safety, contraindications and most common concerns

In terms of safety, the HPV vaccine is one of the most well-studied. The US Centers for Disease Control and Prevention reports more than 15 years of monitoring and research, as well as more than 135 million doses administered. The US National Cancer Institute specifically notes that robust data continues to support the safety and effectiveness of these vaccines. [25]

Typical side effects are usually mild and short-lived. The US National Cancer Institute lists pain, redness, and swelling at the injection site, headache, fatigue, and nausea. Fainting and dizziness have also been reported, especially in adolescents, so it's standard practice to remain under medical supervision for a period of time after vaccination. [26]

Severe allergic reactions are possible, but rare. The U.S. Centers for Disease Control and Prevention (CDC) states that anaphylaxis after vaccination is rare but requires immediate medical attention. Therefore, a severe allergic reaction to a previous dose or a vaccine component is considered a contraindication to further administration. [27]

One of the most persistent myths concerns fertility. The US National Cancer Institute clearly states that there is no evidence linking vaccines to infertility or autoimmune diseases. The US Centers for Disease Control and Prevention, on the contrary, emphasizes that refusing vaccination leaves a person at risk of precancer and cancer, and that treatment for these diseases can limit the ability to have children, for example due to cervical or uterine surgery, chemotherapy, or radiation therapy. [28]

Routine vaccination is not recommended during pregnancy. The U.S. Centers for Disease Control and Prevention recommends delaying the start of the course or subsequent doses until after pregnancy. However, accidental administration of a dose before a woman knows she is pregnant is not considered a cause for alarm: there is no evidence of a link to adverse pregnancy outcomes, but clinical studies have not been specifically conducted in pregnant women. [29]

Situation	What is considered the correct tactic?
Pain and redness at the injection site	This is usually an expected short-term reaction.
Dizziness or lightheadedness	A short observation period is required after vaccination.
Severe allergic reaction to a previous dose	Further administration is contraindicated.
Yeast allergy with nonavalent vaccine	Requires consideration as a contraindication
A minor cold without serious condition	This is usually not a reason to delay vaccination.
Pregnancy	The start and continuation of the course are usually postponed until the end of pregnancy.

Sources for table: US Centers for Disease Control and Prevention and US National Cancer Institute. [30]

Why vaccination doesn't replace screening and what to do after vaccination

One of the most common mistakes is to assume that cervical screening can be forgotten after vaccination. This is incorrect. The US Centers for Disease Control and Prevention clearly emphasizes that the vaccine does not replace routine screening, and the US National Cancer Institute points out that even with modern prevention, screening remains necessary because no vaccine covers absolutely all oncogenic types and because some people may be infected even before vaccination. [31]

Modern prevention logic consists of two sequential levels. The first is to prevent infection with the most dangerous types of the virus through vaccination. The second is to promptly detect precancerous changes in those who have already developed the risk. This is why the World Health Organization links vaccination, screening, and treatment into a single strategy, rather than viewing vaccination as a completely independent solution. [32]

The timing and type of screening vary by country. The US National Cancer Institute cites the American Cancer Society's recommendations: begin screening at age 25 and test for human papillomavirus (HPV) every 5 years until age 65, and if this option is unavailable, use other acceptable schedules. However, another rule is more important in practice: after vaccination, follow the national screening schedule in effect in your country of residence. [33]

It's also important to understand the limitations of the vaccine itself. It doesn't cure an existing infection, doesn't remove existing precancerous cells, and doesn't eliminate the need for follow-up after an abnormal screening result. It's a preventative measure for the future, not a treatment for an already established condition. This is why timeliness is especially important: the earlier the vaccination is administered, the higher the chance that the virus won't have time to take hold. [34]

The most common sense approach is to get vaccinated on time, keep up with screenings as adults, and not confuse the absence of symptoms with the absence of risk. Cervical cancer develops slowly and can remain asymptomatic for a long time, so prevention is always better and safer than treatment once the disease has developed. [35]

After vaccination	What to do next
The course was completed successfully.	Consider yourself protected, but don't cancel screening
The vaccination was administered after the onset of sexual activity.	Understand that benefits are possible, but not absolute.
An abnormal screening result was received.	Follow the check-up route rather than relying on vaccination status
There is a missed dose	Check the course continuation according to the local calendar
No symptoms	Participate in age-appropriate screening anyway
There is an immunodeficiency	Follow a more careful vaccination and monitoring plan

Sources for table: US Centers for Disease Control and Prevention, US National Cancer Institute, World Health Organization. [36]

FAQ

Is it true that this vaccine is only for girls
? No. The main goal of the global program is to prevent cervical cancer, so the World Health Organization prioritizes girls aged 9-14. However, the virus also causes other tumors, so vaccinating boys is also recommended in many programs and is considered a useful measure for personal and population protection. [37]

If sexual activity has already begun, vaccination is no longer beneficial
. No. The effect is usually lower than before the onset of sexual activity, because the likelihood of prior exposure to the virus is higher. However, the US National Cancer Institute points out that a person may still receive residual benefit even if they have already been infected with one or more types, because the vaccine covers more than one type of the virus. [38]

Can I complete the course with just one dose?
The answer depends on the country, age, and immune status. The World Health Organization allows single-dose schedules for some age groups, but many national schedules still use two or three doses. It's important to follow the current schedule of the country where vaccination is administered, not the general guidelines. [39]

If a dose is missed, do you need to start over?
Usually not. The National Cancer Institute and the Centers for Disease Control and Prevention (CDC) state that if a course is interrupted, it should generally be continued rather than restarted, taking into account the doses already received and the minimum intervals. The specific schedule should be determined by a doctor or vaccination clinic according to local regulations. [40]

Can the vaccine cause infertility?
There is no evidence to support this. The US National Cancer Institute explicitly notes the lack of evidence linking it to infertility, and the US Centers for Disease Control and Prevention reminds that treatment for precancer and cervical cancer can worsen reproductive outcomes. [41]

Is screening necessary after vaccination
? Yes, it is. The US Centers for Disease Control and Prevention clearly states that vaccination is not a substitute for screening, and the US National Cancer Institute continues to include screening in standard preventive care even after vaccination. [42]

What to do if you discover you're pregnant after you've administered a dose:
Don't panic. The US Centers for Disease Control and Prevention recommends simply delaying subsequent doses until after the pregnancy is complete. An accidental dose administered alone is not considered a proven risk to the fetus. [43]

What are the most common side effects?
The most common are local pain, redness, and swelling, as well as headache, fatigue, and nausea. Fainting and dizziness have been reported, especially in adolescents, so a short observation period is necessary after the injection. Severe allergic reactions are rare. [44]

How convincing is the evidence that the vaccine actually prevents cancer, not just infection?
This evidence is already very convincing. The US National Cancer Institute cites a large Swedish study that showed a nearly 90% reduction in the risk of invasive cervical cancer in those vaccinated before age 17, and the US Centers for Disease Control and Prevention has recorded a significant reduction in severe precancers in young women during the vaccination era. [45]